CD4 and acute myeloid leukemia: Compared to HDs, AML patients tended to have a decreased proportion of CD4 Tn (median (range) 25.3% (2.5%-68.2%) vs 30.3% (17.7%-52.5%), P = 0.10), as well as an increased proportion of CD4 Teff (2.7% (0.2%-53.0%) vs 1.7% (0.5%-8.9%), P = 0.083).